This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1998;280:1211-1213.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE OLD ADAGE "an ounce of prevention is worth a pound of cure" is one that the National Institutes of Health's (NIH's) Office of AIDS Research (OAR) and its new director are taking to heart.

The OAR, the entity that sets the scientific agenda for all AIDS research conducted or supported by the NIH, is placing a new emphasis on research for a vaccine and other preventive strategies aimed at curbing the spread of HIV, said Neal Nathanson, MD. During a recent interview in Bethesda, Md, Nathanson, a viral epidemiologist who assumed the directorship of the office on July 1, described his vision of how the $1.73 billion NIH-funded research effort should be directed.

Neal Nathanson, MD, director of the Office of AIDS Research at the National Institutes of Health. (Photo credit: Office of AIDS Research.)

The OAR decides which general areas of research are priorities and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?